FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:248-255 July 26, 2001 Number 4 Next

	Full Text PDF Editorial by Granstein, R. D. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Psoriatic plaques are characterized by infiltration with CD45RO+ memory effector T lymphocytes. The recombinant protein alefacept binds to CD2 on memory effector T lymphocytes, inhibiting their activation.

Methods In a multicenter, randomized, placebo-controlled, double-blind study, we evaluated alefacept as a treatment for psoriasis. Two hundred twenty-nine patients with chronic psoriasis received intravenous alefacept (0.025, 0.075, or 0.150 mg per kilogram of body weight) or placebo weekly for 12 weeks, with follow-up for 12 additional weeks. Before treatment, the median scores on the psoriasis area-and-severity index were between 14 and 20 in all groups (0 denotes no psoriasis and 72 the most severe disease possible).

Results Alefacept was well tolerated and nonimmunogenic. The mean reduction in the score on the psoriasis area-and-severity index two weeks after treatment was greater in the alefacept groups (38, 53, and 53 percent in the groups receiving 0.025, 0.075, and 0.150 mg per kilogram, respectively) than in the placebo group (21 percent, P<0.001). Twelve weeks after treatment, 28 patients who had received alefacept alone were clear or almost clear of psoriasis. Three patients in the placebo group were clear or almost clear; all three had received additional systemic therapy for psoriasis. Alefacept reduced peripheral-blood memory effector T-lymphocyte (CD45RO+) counts, and the reduction in the number of memory effector T lymphocytes was correlated with the improvement in psoriasis.

Conclusions Treatment with alefacept for 12 weeks is associated with improvement in chronic plaque psoriasis; some patients have a sustained clinical response after the cessation of treatment. Alefacept selectively targets CD45RO+ memory effector T lymphocytes, suggesting that they have a role in the pathogenesis of psoriasis.

Source Information

From the Department of Dermatology, University of Michigan Medical School, and the Dermatology Service, Veterans Affairs Medical Center, Ann Arbor, Mich. (C.N.E.); and the Department of Dermatology, University of Utah Medical School, Salt Lake City (G.G.K.).

Address reprint requests to Dr. Krueger at the Department of Dermatology, University of Utah Health Sciences Center, 50 N. Medical Dr., Salt Lake City, UT 84132.

Full Text of this Article

This article has been cited by other articles:

• Dustin, M. L., Starr, T., Coombs, D., Majeau, G. R., Meier, W., Hochman, P. S., Douglass, A., Vale, R., Goldstein, B., Whitty, A. (2007). Quantification and Modeling of Tripartite CD2-, CD58FC Chimera (Alefacept)-, and CD16-mediated Cell Adhesion. J. Biol. Chem. 282: 34748-34757 [Abstract] [Full Text]  
• MacDonald, A, Burden, A D (2007). Psoriasis: advances in pathophysiology and management. Postgrad. Med. J. 83: 690-697 [Abstract] [Full Text]  
• Gelfand, J. M. (2007). Long-term Treatment for Severe Psoriasis: We're Halfway There, With a Long Way to Go. Arch Dermatol 143: 1191-1193 [Full Text]  
• Legat, F. J., Hofer, A., Wackernagel, A., Salmhofer, W., Quehenberger, F., Kerl, H., Wolf, P. (2007). Narrowband UV-B Phototherapy, Alefacept, and Clearance of Psoriasis. Arch Dermatol 143: 1016-1022 [Abstract] [Full Text]  
• Haider, A. S., Lowes, M. A., Gardner, H., Bandaru, R., Darabi, K., Chamian, F., Kikuchi, T., Gilleaudeau, P., Whalen, M. S., Cardinale, I., Novitskaya, I., Krueger, J. G. (2007). Novel Insight into the Agonistic Mechanism of Alefacept In Vivo: Differentially Expressed Genes May Serve as Biomarkers of Response in Psoriasis Patients. J. Immunol. 178: 7442-7449 [Abstract] [Full Text]  
• Daoussis, D., Antonopoulos, I., Andonopoulos, A. P., Liossis, S.-N. C. (2007). Increased expression of CD154 (CD40L) on stimulated T-cells from patients with psoriatic arthritis. Rheumatology (Oxford) 46: 227-231 [Abstract] [Full Text]  
• Johnston, S. L (2007). Biologic therapies: what and when?. J. Clin. Pathol. 60: 8-17 [Abstract] [Full Text]  
• Beeton, C., Wulff, H., Standifer, N. E., Azam, P., Mullen, K. M., Pennington, M. W., Kolski-Andreaco, A., Wei, E., Grino, A., Counts, D. R., Wang, P. H., LeeHealey, C. J., S. Andrews, B., Sankaranarayanan, A., Homerick, D., Roeck, W. W., Tehranzadeh, J., Stanhope, K. L., Zimin, P., Havel, P. J., Griffey, S., Knaus, H.-G., Nepom, G. T., Gutman, G. A., Calabresi, P. A., Chandy, K. G. (2006). Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc. Natl. Acad. Sci. USA 103: 17414-17419 [Abstract] [Full Text]  
• Toichi, E., Torres, G., McCormick, T. S., Chang, T., Mascelli, M. A., Kauffman, C. L., Aria, N., Gottlieb, A. B., Everitt, D. E., Frederick, B., Pendley, C. E., Cooper, K. D. (2006). An Anti-IL-12p40 Antibody Down-Regulates Type 1 Cytokines, Chemokines, and IL-12/IL-23 in Psoriasis. J. Immunol. 177: 4917-4926 [Abstract] [Full Text]  
• Beeton, C., Chandy, K. G. (2005). Potassium Channels, Memory T Cells, and Multiple Sclerosis. Neuroscientist 11: 550-562 [Abstract]  
• Gottlieb, A B (2005). Alefacept for psoriasis and psoriatic arthritis. Ann Rheum Dis 64: iv58-iv60 [Abstract] [Full Text]  
• Chi, G. C.-L., Hsu, F.-S., Yang, C.-C., Wei, J. C.-C. (2005). Scleroderma and failed response to alefacept. Rheumatology (Oxford) 44: 1328-1330 [Full Text]  
• Schön, M. P., Boehncke, W.-H. (2005). Psoriasis. NEJM 352: 1899-1912 [Full Text]  
• Chamian, F., Lowes, M. A., Lin, S.-L., Lee, E., Kikuchi, T., Gilleaudeau, P., Sullivan-Whalen, M., Cardinale, I., Khatcherian, A., Novitskaya, I., Wittkowski, K. M., Krueger, J. G. (2005). Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc. Natl. Acad. Sci. USA 102: 2075-2080 [Abstract] [Full Text]  
• Sugiyama, H., Gyulai, R., Toichi, E., Garaczi, E., Shimada, S., Stevens, S. R., McCormick, T. S., Cooper, K. D. (2005). Dysfunctional Blood and Target Tissue CD4+CD25high Regulatory T Cells in Psoriasis: Mechanism Underlying Unrestrained Pathogenic Effector T Cell Proliferation. J. Immunol. 174: 164-173 [Abstract] [Full Text]  
• Goedkoop, A Y, Kraan, M C, Teunissen, M B M, Picavet, D I, de Rie, M A, Bos, J D, Tak, P P (2004). Early effects of tumour necrosis factor {alpha} blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis 63: 769-773 [Abstract] [Full Text]  
• Walsh, S. R.A., Shear, N. H. (2004). Psoriasis and the new biologic agents: interrupting a T-AP dance. CMAJ 170: 1933-1941 [Abstract] [Full Text]  
• Boyman, O., Hefti, H. P., Conrad, C., Nickoloff, B. J., Suter, M., Nestle, F. O. (2004). Spontaneous Development of Psoriasis in a New Animal Model Shows an Essential Role for Resident T Cells and Tumor Necrosis Factor-{alpha}. J. Exp. Med. 199: 731-736 [Abstract] [Full Text]  
• Krueger, G., Callis, K. (2004). Potential of Tumor Necrosis Factor Inhibitors in Psoriasis and Psoriatic Arthritis. Arch Dermatol 140: 218-225 [Abstract] [Full Text]  
• Stern, R. S. (2003). A Promising Step Forward in Psoriasis Therapy. JAMA 290: 3133-3135 [Full Text]  
• Gordon, K. B., Vaishnaw, A. K., O'Gorman, J., Haney, J., Menter, A. (2003). Treatment of Psoriasis With Alefacept: Correlation of Clinical Improvement With Reductions of Memory T-Cell Counts. Arch Dermatol 139: 1563-1570 [Abstract] [Full Text]  
• Gottlieb, A. B., Matheson, R. T., Lowe, N., Krueger, G. G., Kang, S., Goffe, B. S., Gaspari, A. A., Ling, M., Weinstein, G. D., Nayak, A., Gordon, K. B., Zitnik, R. (2003). A Randomized Trial of Etanercept as Monotherapy for Psoriasis. Arch Dermatol 139: 1627-1632 [Abstract] [Full Text]  
• Kess, D., Peters, T., Zamek, J., Wickenhauser, C., Tawadros, S., Loser, K., Varga, G., Grabbe, S., Nischt, R., Sunderkotter, C., Muller, W., Krieg, T., Scharffetter-Kochanek, K. (2003). CD4+ T Cell-Associated Pathophysiology Critically Depends on CD18 Gene Dose Effects in a Murine Model of Psoriasis. J. Immunol. 171: 5697-5706 [Abstract] [Full Text]  
• Skov, L., Kragballe, K., Zachariae, C., Obitz, E. R., Holm, E. A., Jemec, G. B. E., Solvsten, H., Ibsen, H. H., Knudsen, L., Jensen, P., Petersen, J. H., Menne, T., Baadsgaard, O. (2003). HuMax-CD4: A Fully Human Monoclonal Anti-CD4 Antibody for the Treatment of Psoriasis Vulgaris. Arch Dermatol 139: 1433-1439 [Abstract] [Full Text]  
• Boehncke, W.-H. (2003). Immunomodulatory drugs for psoriasis. BMJ 327: 634-635 [Full Text]  
• Lebwohl, M., Christophers, E., Langley, R., Ortonne, J. P., Roberts, J., Griffiths, C. E. M. (2003). An International, Randomized, Double-blind, Placebo-Controlled Phase 3 Trial of Intramuscular Alefacept in Patients With Chronic Plaque Psoriasis. Arch Dermatol 139: 719-727 [Abstract] [Full Text]  
• Gottlieb, A. (2003). Immunobiologic Agents for the Treatment of Psoriasis: Clinical Research Delivers New Hope for Patients With Psoriasis. Arch Dermatol 139: 791-793 [Full Text]  
• Schwartz, R. S. (2003). Diversity of the Immune Repertoire and Immunoregulation. NEJM 348: 1017-1026 [Full Text]  
• Kosmadaki, M. G., Gilchrest, B. A. (2002). The Demographics of Aging in the United States: Implications for Dermatology. Arch Dermatol 138: 1427-1428 [Full Text]  
• Singri, P., West, D. P., Gordon, K. B. (2002). Biologic Therapy for Psoriasis: The New Therapeutic Frontier. Arch Dermatol 138: 657-663 [Abstract] [Full Text]  
• Lebwohl, M. (2002). New Developments in the Treatment of Psoriasis. Arch Dermatol 138: 686-688 [Full Text]  
• da Silva, A. J., Brickelmaier, M., Majeau, G. R., Li, Z., Su, L., Hsu, Y.-M., Hochman, P. S. (2002). Alefacept, an Immunomodulatory Recombinant LFA-3/IgG1 Fusion Protein, Induces CD16 Signaling and CD2/CD16-Dependent Apoptosis of CD2+ Cells. J. Immunol. 168: 4462-4471 [Abstract] [Full Text]  
• Millard, T. P., Birch, K. E., Young, E. R., Haserick, J. R., Hanauer, L., Ellis, C. N., Krueger, G. G., Granstein, R. D. (2001). Treatment of Plaque Psoriasis. NEJM 345: 1853-1855 [Full Text]  
• (2001). Alefacept Targets Memory Effector T Cells and Improves Psoriasis. Journal Watch Dermatology 2001: 3-3 [Full Text]  
• Granstein, R. D. (2001). New Treatments for Psoriasis. NEJM 345: 284-287 [Full Text]